Component

Human dipeptidyl peptidase 4 / DPP4 / CD26

Human dipeptidyl peptidase 4 / DPP4 / CD26

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.

    Apigenin → Human dipeptidyl peptidase 4 / DPP4 / CD26 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Apigenin", "comparator": "Vehicle", "endpoint": "Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Human colorectal cancer cell line; 30–60 micromolar, 48 hours.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.
    primary_references
    Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894
    source_locator
    Reviewed reference api-cd26; Surface expression is not necessarily catalytic activity, glucose control or an anti-tumor endpoint.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 724–730

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Human colorectal cancer cell line; 30–60 micromolar, 48 hours. · Recorded from source · Recorded from source

    ### api-cd26 Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells. Surface expression is not necessarily catalytic activity, glucose control or an anti-tumor endpoint. Model and exposure: Human colorectal cancer cell line; 30–60 micromolar, 48 hours. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  2. Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.

    Apigenin → Human dipeptidyl peptidase 4 / DPP4 / CD26 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_condition
    Single-agent comparison reported by the study co-administered · Irinotecan Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_condition
    Single-agent comparison reported by the study Apigenin plus irinotecan · Apigenin Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "Apigenin plus irinotecan", "comparator": "Single-agent comparison reported by the study", "endpoint": "Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.", "effect_direction": "increase", "combination": "joint", "conditions": [{"entity_slug": "apigenin", "state": "Apigenin plus irinotecan"}, {"entity_slug": "irinotecan", "state": "co-administered"}]} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Cell-surface CD26 endpoint; the paper also tested other topoisomerase drugs.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay.
    primary_references
    Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894
    source_locator
    Reviewed reference api-irinotecan-cd26; Do not translate this expression interaction into proven synergistic tumor killing or a clinical co-treatment recommendation.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 740–746

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Cell-surface CD26 endpoint; the paper also tested other topoisomerase drugs. · Recorded from source · Recorded from source

    ### api-irinotecan-cd26 Apigenin plus irinotecan increased CD26 expression in the reported HT-29 combination assay. Do not translate this expression interaction into proven synergistic tumor killing or a clinical co-treatment recommendation. Model and exposure: Cell-surface CD26 endpoint; the paper also tested other topoisomerase drugs. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  3. TOP1 knockdown raised basal CD26 expression and occluded the additional CD26 response to apigenin.

    Apigenin → Human dipeptidyl peptidase 4 / DPP4 / CD26 Recorded from sourceungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_condition
    TOP1-knockdown cells without apigenin siRNA knockdown · Human DNA topoisomerase I / TOP1 Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_condition
    TOP1-knockdown cells without apigenin Apigenin after TOP1 knockdown · Apigenin Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "Apigenin after TOP1 knockdown", "comparator": "TOP1-knockdown cells without apigenin", "endpoint": "TOP1 knockdown raised basal CD26 expression and occluded the additional CD26 response to apigenin.", "effect_direction": "no_detected_change", "combination": "joint", "conditions": [{"entity_slug": "apigenin", "state": "Apigenin after TOP1 knockdown"}, {"entity_slug": "human-top1", "state": "siRNA knockdown"}]} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    HT-29 cells; over 75% TOP1 knockdown.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    TOP1 knockdown raised basal CD26 expression and occluded the additional CD26 response to apigenin.
    primary_references
    Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894
    source_locator
    Reviewed reference api-top1-knockdown; Supports pathway involvement for this expression endpoint without identifying a clinical therapeutic interaction.
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 732–738

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · HT-29 cells; over 75% TOP1 knockdown. · Recorded from source · Recorded from source

    ### api-top1-knockdown TOP1 knockdown raised basal CD26 expression and occluded the additional CD26 response to apigenin. Supports pathway involvement for this expression endpoint without identifying a clinical therapeutic interaction. Model and exposure: HT-29 cells; over 75% TOP1 knockdown. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.